Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients

Paolo Marzullo, Diego Ferone, Carolina Di Somma, Rosario Pivonello, Mariagiovanna Filippella, Gaetano Lombardi, Annamaria Colao

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The aim of this study was to evaluate the efficacy of a 6-month treatment with lanreotide (LAN) (60-90 mg/month) alone and combined with cabergoline (CAB) (1.5-3 mg/week) in 10 acromegalic patients previously demonstrated to be poor responders to octreotide (OCT) (0.6 mg/day) alone and combined with quinagolide (CV) (0.6 mg/day). All patients had previously undergone unsuccessful surgery and none of them received radiotherapy. Immunohistochemistry showed intense positive GH staining in all adenomas, positive PRL staining in 5 adenomas and faint ACTH or FSH/LH positive staining in other 2 adenomas. Moderately elevated serum PRL levels (35 and 47 ng/ml) were recorded in two patients. Fasting plasma IGF-I and serum GH levels were assayed at baseline and 30, 60, 90 and 120 days after each treatment. Gallbladder ultrasonography and sellar MRI were performed before and after 6 months of OCT and LAN treatments. After OCT treatment circulating GH and IGF-I levels remained elevated in all patients, while after 3 months of combined OCT+CV treatment, serum GH levels were suppressed (below 2.5 ng/ml) in only 1 patient. Significant increase of the percent GH (83.9±4.3 vs. 70.3±5.6%, p

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalPituitary
Volume1
Issue number2
Publication statusPublished - 1999

Fingerprint

Octreotide
Adenoma
Staining and Labeling
Insulin-Like Growth Factor I
Serum
Therapeutics
Gallbladder
Adrenocorticotropic Hormone
Fasting
Ultrasonography
Radiotherapy
Immunohistochemistry
cabergoline
lanreotide

Keywords

  • Acromegaly
  • Cabergoline
  • Dopamine-agonists
  • GH
  • IGF-I
  • Lanreotide
  • Octreotide
  • Quinagolide
  • Somatostatin analogs

ASJC Scopus subject areas

  • Endocrinology

Cite this

Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients. / Marzullo, Paolo; Ferone, Diego; Di Somma, Carolina; Pivonello, Rosario; Filippella, Mariagiovanna; Lombardi, Gaetano; Colao, Annamaria.

In: Pituitary, Vol. 1, No. 2, 1999, p. 115-120.

Research output: Contribution to journalArticle

Marzullo, Paolo ; Ferone, Diego ; Di Somma, Carolina ; Pivonello, Rosario ; Filippella, Mariagiovanna ; Lombardi, Gaetano ; Colao, Annamaria. / Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients. In: Pituitary. 1999 ; Vol. 1, No. 2. pp. 115-120.
@article{99deb3ffabfe4d32b9d1f6cb3cf759df,
title = "Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients",
abstract = "The aim of this study was to evaluate the efficacy of a 6-month treatment with lanreotide (LAN) (60-90 mg/month) alone and combined with cabergoline (CAB) (1.5-3 mg/week) in 10 acromegalic patients previously demonstrated to be poor responders to octreotide (OCT) (0.6 mg/day) alone and combined with quinagolide (CV) (0.6 mg/day). All patients had previously undergone unsuccessful surgery and none of them received radiotherapy. Immunohistochemistry showed intense positive GH staining in all adenomas, positive PRL staining in 5 adenomas and faint ACTH or FSH/LH positive staining in other 2 adenomas. Moderately elevated serum PRL levels (35 and 47 ng/ml) were recorded in two patients. Fasting plasma IGF-I and serum GH levels were assayed at baseline and 30, 60, 90 and 120 days after each treatment. Gallbladder ultrasonography and sellar MRI were performed before and after 6 months of OCT and LAN treatments. After OCT treatment circulating GH and IGF-I levels remained elevated in all patients, while after 3 months of combined OCT+CV treatment, serum GH levels were suppressed (below 2.5 ng/ml) in only 1 patient. Significant increase of the percent GH (83.9±4.3 vs. 70.3±5.6{\%}, p",
keywords = "Acromegaly, Cabergoline, Dopamine-agonists, GH, IGF-I, Lanreotide, Octreotide, Quinagolide, Somatostatin analogs",
author = "Paolo Marzullo and Diego Ferone and {Di Somma}, Carolina and Rosario Pivonello and Mariagiovanna Filippella and Gaetano Lombardi and Annamaria Colao",
year = "1999",
language = "English",
volume = "1",
pages = "115--120",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients

AU - Marzullo, Paolo

AU - Ferone, Diego

AU - Di Somma, Carolina

AU - Pivonello, Rosario

AU - Filippella, Mariagiovanna

AU - Lombardi, Gaetano

AU - Colao, Annamaria

PY - 1999

Y1 - 1999

N2 - The aim of this study was to evaluate the efficacy of a 6-month treatment with lanreotide (LAN) (60-90 mg/month) alone and combined with cabergoline (CAB) (1.5-3 mg/week) in 10 acromegalic patients previously demonstrated to be poor responders to octreotide (OCT) (0.6 mg/day) alone and combined with quinagolide (CV) (0.6 mg/day). All patients had previously undergone unsuccessful surgery and none of them received radiotherapy. Immunohistochemistry showed intense positive GH staining in all adenomas, positive PRL staining in 5 adenomas and faint ACTH or FSH/LH positive staining in other 2 adenomas. Moderately elevated serum PRL levels (35 and 47 ng/ml) were recorded in two patients. Fasting plasma IGF-I and serum GH levels were assayed at baseline and 30, 60, 90 and 120 days after each treatment. Gallbladder ultrasonography and sellar MRI were performed before and after 6 months of OCT and LAN treatments. After OCT treatment circulating GH and IGF-I levels remained elevated in all patients, while after 3 months of combined OCT+CV treatment, serum GH levels were suppressed (below 2.5 ng/ml) in only 1 patient. Significant increase of the percent GH (83.9±4.3 vs. 70.3±5.6%, p

AB - The aim of this study was to evaluate the efficacy of a 6-month treatment with lanreotide (LAN) (60-90 mg/month) alone and combined with cabergoline (CAB) (1.5-3 mg/week) in 10 acromegalic patients previously demonstrated to be poor responders to octreotide (OCT) (0.6 mg/day) alone and combined with quinagolide (CV) (0.6 mg/day). All patients had previously undergone unsuccessful surgery and none of them received radiotherapy. Immunohistochemistry showed intense positive GH staining in all adenomas, positive PRL staining in 5 adenomas and faint ACTH or FSH/LH positive staining in other 2 adenomas. Moderately elevated serum PRL levels (35 and 47 ng/ml) were recorded in two patients. Fasting plasma IGF-I and serum GH levels were assayed at baseline and 30, 60, 90 and 120 days after each treatment. Gallbladder ultrasonography and sellar MRI were performed before and after 6 months of OCT and LAN treatments. After OCT treatment circulating GH and IGF-I levels remained elevated in all patients, while after 3 months of combined OCT+CV treatment, serum GH levels were suppressed (below 2.5 ng/ml) in only 1 patient. Significant increase of the percent GH (83.9±4.3 vs. 70.3±5.6%, p

KW - Acromegaly

KW - Cabergoline

KW - Dopamine-agonists

KW - GH

KW - IGF-I

KW - Lanreotide

KW - Octreotide

KW - Quinagolide

KW - Somatostatin analogs

UR - http://www.scopus.com/inward/record.url?scp=0033288398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033288398&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 115

EP - 120

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 2

ER -